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Acute myeloid leukemia (AML), a blood/bone marrow cancer, is a severe and often fatal
malignancy. AML cells are capable of impairing the anti-cancer activities of cytotoxic
lymphoid cells. This includes the inactivation of natural killer (NK) cells and killing of T
lymphocytes. Here we report for the first time that V-domain Ig-containing suppressor of T
cell activation (VISTA), a protein expressed by T cells, recognizes galectin-9 secreted by
AML cells as a ligand. Importantly, we found that soluble VISTA released by AML cells
enhances the effect of galectin-9, most likely by forming multiprotein complexes on the
surface of T cells and possibly creating a molecular barrier. These events cause changes
in the plasma membrane potential of T cells leading to activation of granzyme B inside
cytotoxic T cells, resulting in apoptosis.
Keywords: Galectin-9, VISTA, T cells, NK cells, acute myeloid leukemia, immune escapeINTRODUCTION
Acute myeloid leukemia (AML) is a blood/bone marrow cancer originating from myeloid
precursors, which rapidly progresses into a systemic and often a fatal malignancy. Human AML
cells operate a variety of biochemical mechanisms which allow them to escape host immune
surveillance (1). These molecular pathways cause impairment of the anti-cancer activities of natural
killer (NK) cells and cytotoxic T cells which could otherwise attack and kill AML cells (1, 2). It has
recently been reported that one of these immune evasion pathways includes high expression/
secretion of the protein galectin-9, its receptor and its possible trafficker/carrier (as with all galectins,
galectin-9 requires a carrier protein-trafficker to be secreted) - the T cell immunoglobulin andorg November 2020 | Volume 11 | Article 5805571
Yasinska et al. Galectin-9 and VISTA Ligand-Receptor Interactionsmucin domain containing protein 3 (Tim-3) (3–6). Galectin-9
has two similar ligand/sugar-binding domains (7, 8). These
domains are fused together by a peptide linker, which could be
of three different sizes (due to alternative splicing), that
determines the presence of three isoforms of galectin-9 in
human cells (7, 8).
Galectin-9 is actively engaged in impairing the cytotoxic
activities of NK cells and can, in addition to suppression, induce
apoptotic death of cytotoxic T cells (5, 9–12). However, the
mechanisms underlying these differential effects remain unknown.
It has been reported that cytotoxic lymphoid cell-based Tim-3 is
involved in these effects as a receptor. Tim-3 is expressed by both T
cells andNK cells, however, immunosuppressive effects of galectin-9
vary in these cells, suggesting that some additional factors determine
the differential responses of NK and T cells to galectin-9 (2, 5). We
hypothesized that one of these additional factors could be another
immunoglobulin (Ig) superfamily member, known as V-domain Ig-
containing suppressor of T cell activation (VISTA), which is
expressed in both myeloid and T cells, while NK cells express
barely detectable amounts of VISTA (13–15). VISTA has been
reported to display both receptor and ligand properties (13–15).
Given the similarities between Tim-3 and VISTA structural
organizations, we proposed that galectin-9 can interact with T
cell-based VISTA causing downstream effects and thus might
determine differences in NK and T cell responses to galectin-9.
Here we report for the first time that galectin-9 binds VISTA,
most likely as a ligand. Binding was verified using co-
immunoprecipitation assays and biophysical methods –
synchrotron radiation circular dichroism (SRCD) spectroscopy
and surface plasmon resonance (SPR). We confirmed that human
Tcells, butnotNKcells (noVISTAproteinwasdetectedbyWestern
blot), express VISTA protein. Both VISTA and Tim-3 mediate
galectin-9-induced downregulation of granzyme B (pro-apoptotic
protease) release from T cells, increasing the presence of this
enzyme inside the T cells which produce it and possibly causing
activationof the caspase-3pro-apoptoticpathway.Furthermore,we
found that primary human AML cells secrete high amounts of
VISTA compared to healthy mononuclear leukocytes. Exposure of
phorbol 12-myristate 13-acetate (PMA–anactivatorofgranzymeB
production and release)-activated Jurkat T cells to human galectin-
9 and soluble VISTA significantly affects their polarization/
membrane potential thus preventing granzyme B release. The
same effect was observed in primary human T cells but not in NK
cells.We hypothesized that galectin-9 and soluble VISTA can form
multiprotein agglomerates engagingwith Tim-3 andVISTA on the
surface ofT cells (butnotNKcellswhichdidnot showexpressionof
detectable amounts ofVISTAprotein inWestern blot analysis) thus
affecting the cell polarity/plasma membrane potential and leading
to granzyme B-mediated self-killing.MATERIALS AND METHODS
Materials
RPMI-1640 cell culture medium, fetal bovine serum and
supplements as well as basic laboratory chemicals were
purchased from Sigma (Suffolk, UK). Microtitre plates forFrontiers in Immunology | www.frontiersin.org 2Enzyme-Linked Immunosorbent Assay (ELISA) were provided
by Oxley Hughes Ltd (London, UK). Rabbit antibodies against
VISTA, galectin-9, granzyme B and CD3 were purchased from
Abcam (Cambridge, UK). Goat antibody against VISTA was
purchased from Santa Cruz Biotechnology (Heidelberg,
Germany). Antibodies against actin were purchased from
Abcam (Cambridge, UK) and Proteintech (Manchester, UK).
Mouse antibody against PARP was obtained from Enzo Life
Sciences (Exeter, UK). Goat anti-mouse, anti-rabbit and donkey
anti-goat fluorescence dye-labeled antibodies were obtained
from Li-COR (Lincoln, Nebraska USA). ELISA-based assay
kits for detection of galectin-9, Tim-3 and VISTA as well as
human recombinant galectin-9 and anti-VISTA antibody
reacting to native protein were purchased from Bio-Techne
(R&D Systems, Abingdon, UK). VISTA-Fc and Fc human
recombinant proteins were obtained from Sino Biological US
Inc (Wayne, PA, USA). Anti-Tim-3 mouse monoclonal
antibodies (detection and neutralizing) as well as human Ig-
like V-type domain of Tim-3 (amino acid residues 22-124),
expressed and purified from E. coli (16) were used in our
work. Antibodies for fluorescent microscopy and flow
cytometry as well as annexin V/propidium iodide apoptosis
assay kits were from Invitrogen (Carlsbad, USA). All other
chemicals purchased were of the highest grade of purity
commercially available.
Cell Lines and Primary Human Samples
THP-1 human myeloid leukemia monocytes, Jurkat T cells and
MCF-7 human breast cancer cells were obtained from the
European Collection of Cell Cultures (Salisbury, UK). HaCaT
keratinocytes were purchased from CLS (Cell Line Service,
Germany) and cultured according to the CLS recommendations.
Blood plasma of healthy human donors was obtained as
described (17) from buffy coat blood (purchased from healthy
donors undergoing routine blood donation) which was purchased
from the National Health Blood and Transfusion Service (NHSBT,
UK) following ethical approval (REC reference: 16-SS-033).
Mononuclear-rich leukocytes were isolated using Ficoll-density
centrifugation according to the manufacturer’s protocol. Cell
numbers were determined using haemocytometers and then
diluted with HEPES-buffered Tyrode’s solution before treatment
as indicated in the text. NK cells were purified as previously
described (5). Primary human T cells were purified using a
commercial T cell purification kit (EasySep Human T Cell
Isolation Kit, StemCell Technologies, Cologne, Germany).
Primary human AML plasma samples and cells obtained from
newly diagnosed AML patients were provided by the sample bank
of University Medical Centre Hamburg-Eppendorf (Ethik-
Kommission der Ärztekammer Hamburg, reference: PV3469).
Cells were kept in IMDM medium containing 15% BIT 9500
serum substitute, 100 µM mercaptoethanol, 100 ng/ml stem cell
factor (SCF), 50 ng/ml FLT3, 20 ng/ml G-CSF, 20 ng/ml IL-3, 1 µM
UM729 and 500 nM stemregenin 1 (SR1).
Western Blot Analysis
VISTA, Tim-3, PARP cleavage and CD3 levels were analyzed by
Western blot and compared to the amounts of b-actin (proteinNovember 2020 | Volume 11 | Article 580557
Yasinska et al. Galectin-9 and VISTA Ligand-Receptor Interactionsloading control), as previously described (18). Briefly, cells were
lysed in using the buffer (50 mM Tris–HCl, 5 mM EDTA, 150
mM NaCl, 0.5% Nonidet-40, 1 mM PMSF, pH 8.0). After
centrifugation, protein content in supernatants was analyzed
using Bradford assay. Proteins were resolved using SDS–
polyacrylamide gels followed by blotting onto nitrocellulose
membranes. Molecular weights were calibrated in proportion
to the running distance of rainbow markers. All primary
antibodies were diluted 1:1000. Li-COR goat secondary
antibodies (dilution 1:2000), conjugated with fluorescent dyes,
were used in accordance with manufacturer’s protocol to
visualize target proteins (using a Li-COR Odyssey imaging
system). Western blot data were analyzed using Odyssey
software and values were subsequently normalized against
those of b-actin (loading control).
In Vitro Assay of VISTA-Galectin-9
Interactions
This assay was performed as described before for Tim-3-
galectin-9 interactions. Briefly, VISTA protein from Jurkat T
cell lysates was first precipitated on Maxisorp ELISA plates. For
this purpose ELISA plates were coated overnight with goat
antibody against VISTA. Plates were then blocked with 2%
BSA. Tissue culture medium obtained from culturing PMA-
treated THP-1 or MCF 7 (negative control) cells was then
applied for 2 h at room temperature, followed by extensive
washing with TBST buffer. Proteins were then extracted using
0.2 M glycine-HCl buffer (pH 2.0). Extracts were neutralized
using lysis buffer and subjected to Western blot analysis (samples
where not boiled in this case) using rabbit anti-galectin-9 and
mouse anti-Tim-3 antibodies as described before (4) and above.
Alternatively, the format was subjected to measurement of
bound galectin-9 using an ELISA kit according to the
manufacturer’s protocol.
Enzyme-Linked Immunosorbent Assays
(ELISAs)
Secreted galectin-9 and soluble VISTA, were measured either in
cell culture medium or in blood plasma by ELISA using R&D
Systems kits according to manufacturer’s protocols.
On-Cell Western Analysis
We employed LI-COR on-cell Western (OCW) assay to analyze
total Tim-3 and VISTA expressions in the studied cells using the
Li-COR Odyssey imaging system as previously described (4, 19).
Fluorescent Microscopy and Flow
Cytometry
Cells were cultured overnight on 12 mm cover slips in 24-well
plates and then fixed/permeabilised for 20 min with ice-cold
MeOH/acetone (1:1). Alternatively cells were fixed in a freshly
prepared 2% paraformaldehyde, washed three times with PBS
and then permeabilised with 0.1% TX-100. Cover slips were
blocked for 1h at RT with 10% goat serum in PBS. Cells were
stained with anti-VISTA antibody overnight at 4°C. As
secondary antibodies were used goat-anti-mouse Alexa FluorFrontiers in Immunology | www.frontiersin.org 3488 for 45 min at RT. The nuclei were stained with 4′,6-
diamidino-2-phenylindole (DAPI). The preparations were
analyzed using Olympus microscope as described previously
(16, 20). Images were collected and analyzed using proprietary
image acquisition software.
Flow cytometry experiments were performed in accordance
with a previously described protocol (21). Briefly, cells were
collected and fixed with 2% paraformaldehyde and permeabilised
with 0.1% TX-100. Cells were stained with mouse anti-VISTA
antibodies conjugated with Alexa Fluor 488 o/n at 4°C. Mean
fluorescence intensity of stained cells was measured and analyzed
using a FACSCalibur analyzer and the CEllQuest Pro Software
(Becton Dickinson, USA).
Measurement of Granzyme B and
Caspase-3 Activities
Granzyme B activity in cell lysates was measured using a
fluorometric assay based on the ability of the enzyme to cleave
the fluorogenic substrate Ac-IEPD-AFC (Sigma). Caspase-3
activity was measured spectrophotometrically based on its
ability to cleave its specific substrate Ac-DEVD-pNA. Both
assays were performed according to the manufacturers’
protocol. In-cell activity of granzyme B (granzyme B catalytic
activity in living cells) was measured by incubation of living cells
with 150 µMAc-IEPD-AFC (granzymeB substrate) for 1 h at 37°C
in sterile PBS. This did not affect viability of the cells as
measured by MTS assay (Promega kit, measurements were
performed according to the manufacturer’s protocol). Total
cell fluorescence was then measured in living cells (22) using
excitation and emission wavelengths recommended in the Ac-
IEPD-AFC manufacturer’s (Sigma) protocol. An equal number
of cells, which were not exposed to granzyme B substrate, were
used as a control.
Apoptosis and Cell Viability Assays
The percentage of apoptotic cells was measured using an annexin
V/propidium iodide assay kit by flow cytometry according to the
manufacturer’s (Invitrogen) instructions. Cell viability was
assessed using an MTS assay kit (Promega) according to the
manufacturer’s protocol.
Characterization of Cell Membrane
Potential
This was performed using a DiBAC4(3) fluorescent probe where
the intensity of accumulation in a cell is proportional to its
depolarization. This assay was performed as recommended by
the manufacturer and described before (23).
Synchrotron Radiation Circular Dichroism
Spectroscopy
Human recombinant VISTA, galectin-9 and Tim-3 as well as
VISTA-galectin-9 or VISTA-galectin-9-Tim-3 complexes were
characterized using SRCD spectroscopy at beam line 23,
Diamond Light Source (Didcot, UK). SRCD measurements
were performed with 0.2 µg/ml of samples using a 1 cm path
length cell, 3 mm aperture diameter and 40 µl capacity usingNovember 2020 | Volume 11 | Article 580557
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bandwidth at 23°C (24–26). The obtained results were analyzed
with the help of CDApps (25) and OriginPro™.
Surface Plasmon Resonance
This assay was performed using a CM5 sensor chip. A Biacore
amino coupling kit was employed to immobilize galectin-9 on
the chip surface and VISTA (as a fusion protein with Fc) as well
as Fc alone were flowed through in order to assess interactions
using a Biacore T200 instrument. Data analysis was performed
using Biacore T200 software and also using exponential decay
(GraphPad Prism), taking into account both association and
dissociation (27).
Statistical Analysis
Each experiment was performed at least three times and
statistical analysis when comparing two events at a time was
conducted using a two-tailed Student’s t-test. Multiple
comparisons were performed by ANOVA. Post-hoc Bonferroni
correction was applied. Statistical probabilities (p) were
expressed as * when p<0.05; **, p<0.01 and *** when p<0.001.RESULTS
Galectin-9 Specifically Binds VISTA With
High Affinity
In order to assess the possible interactions of VISTA with
galectin-9 we used 96 well ELISA plates coated with goat anti-
VISTA antibody. We then immunoprecipitated VISTA from
Jurkat T cells by exposing the plate to Jurkat T cell lysates
(Figures 1A, B) as previously described (4). We found that these
cells express VISTA protein, while we could not detect any
VISTA in primary NK cell lysates (Figure 1C; a full
comparison of fluorescence observed for VISTA in Western
blot analysis conducted in Jurkat T, primary human NK, THP-
1, primary human AML and primary human T cells is presented
in Supplementary Figure 1). When VISTA was captured and
attached to an ELISA plate surface through the antibody, we
exposed this di-protein complex to medium obtained from
culturing THP-1 human AML cells for 24 h in the presence of
100 nM PMA (in order to maximize galectin-9 secretion (5)),
which triggered the cells to produce around 6 ng of galectin-9 per
106 cells (as measured by ELISA). As a negative control we used
medium obtained from culturing MCF-7 breast cancer cells for
24 h in the presence of 100 nM PMA. MCF-7 cells express but
don’t secrete any galectin-9 (6) that was also confirmed here by
ELISA where no release of galectine-9 was detected)). After 2 h of
exposure we either eluted bound proteins using glycine-HCl
buffer (pH 2.0) and subjected the extract to Western blot analysis
(4) (Figure 1A) or assessed galectin-9 concentrations by ELISA
(Figure 1B). Western blot analysis demonstrated that galectin-9
was present in samples exposed to the medium from THP-1 but
not MCF-7 cells (Figure 1A). ELISA analysis also confirmed the
presence of galectin-9 in samples exposed to the medium from
THP-1 but not MCF-7 cells (Figure 1B). Importantly, exposureFrontiers in Immunology | www.frontiersin.org 4of the ELISA plate coated with anti-VISTA antibody (and BSA-
blocked) to galectin-9 containing medium did not result in any
signal, also confirming specific interaction of galectin-9 with
VISTA (data not shown). SRCD spectroscopy showed that
human recombinant galectin-9 binds VISTA causing
conformational changes (Figure 1D) and titration showed that
the Kd of this binding is 18 nM which confirms a relatively high
binding affinity (Figure 1E). Since VISTA was used as an
immunoglobulin fragment crystallisable region (VISTA-Fc)
fusion protein, we checked if Fc can bind galectin-9, but the
result was negative, suggesting that there is no specific
interaction between these two proteins (Figure 1F). For the
experiment shown in Figure 1D the observed spectra of Fc
protein were subtracted from those of VISTA-Fc.
In order to further confirm specific interactions between
galectin-9 and VISTA, we performed SPR analysis with
galectin-9 immobilized on a CM5 Biacore sensor chip with
either VISTA-Fc or Fc flowing through the cell. The binding of
VISTA but not Fc was confirmed and we used three different
approaches to calculate the Kd – a Lineweaver–Burk type plot,
Biacore T200 software and GraphPad prism (exponential decay,
association and dissociation approach), see Supplementary
Figure 2. The Kd in all cases was approximately 100 nM
(specific values for each method are shown in Supplementary
Figure 2). These results confirmed specific binding of galectin-9
to VISTA.
VISTA Mediates Galectin-9-Induced
Suppression of Granzyme B Release and
Pro-Apoptotic Processes in T Cells
To assess the possible role of granzyme B, a pro-apoptotic
proteolytic enzyme produced mainly by cytotoxic T cells and NK
cells, in galectin-9-induced killing of T cells, we co-cultured THP-1
human AML cells and Jurkat T cells (at a ratio 1:1; Jurkat T cells
express high amounts of VISTA and can express granzyme B and
release this enzyme upon stimulation with PMA (28, 29), which
activates granzyme B expression through NF-kB (29)). Both cell
types were pre-treated for 24 h with 100 nMPMA before being co-
cultured inPMA-freemedium. InductionofgranzymeBexpression
by PMA in Jurkat T cells was confirmed by Western blot analysis
(Supplementary Figure 3). This led to the adhesion of THP-1 cells
and caused them to release high levels of galectin-9 (>6 ng per 106
cells over 16 h of incubation in PMA-free medium after pre-
treatment) and activation of granzyme B in Jurkat T cells (these
cells did not adhere to the surface and remained in suspension) as
well as upregulating their capability to release this enzyme. Equal
amounts of cellswere co-cultured for 16h (Figure2A) andgalectin-
9 release (Figure 2B) as well as granzyme B activity (Figure 2C)
were measured in both cell types. Importantly, PMA-pre-treated
THP-1 cells released around 250 pg of soluble VISTA per 106 cells
during 16 h of post-PMA incubation (as measured by ELISA).
We found that PMA-treated THP-1 cells produced high levels
of galectin-9 which were slightly reduced in the presence of
Jurkat T cells (Figure 2B), suggesting most likely the interaction
of galectin-9 with surface receptors of Jurkat T cells. Importantly,
resting Jurkat T cells, pre-treated for 24 h with 100 nM PMA,November 2020 | Volume 11 | Article 580557
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Yasinska et al. Galectin-9 and VISTA Ligand-Receptor Interactionsduring 16 h of post-PMA incubation in PMA-free medium
released ca. 300 pg galectin-9 per 106 cells and did not release
detectable amounts of soluble VISTA (as measured by ELISA).
Resting PMA-pre-treated THP-1 cells did not show detectable
granzyme B activity. In the presence of Jurkat T cells granzyme B
was almost equally distributed between THP-1 and Jurkat T cells
(Figure 2C). Importantly, Ac-IEPD-AFC has a similar amino
acid sequence to the caspase 8-specific substrate, IETD (often
derivative of type Ac-IETD is used). Therefore, caspase 8 has
lower affinity to Ac-IEPD-AFC and can thus cleave it. To rule
out the involvement of caspase 8 in the effects observed, we
measured Ac-IEPD-AFC cleavage in the presence of the 100 µM
granzyme B inhibitor benzyloxycarbonyl-ala-ala-asp-
chloromethylketone (Z-AAD-CMK) in the reaction mixture.
The presence of this inhibitor completely abolished the
observed proteolytic activities which allowed us to conclude
that the effects seen where caused by granzyme B and not by
caspase 8 or other proteolytic enzymes (Supplementary Figure
4). When the co-culture was performed in the presence of 5 mg/
ml anti-VISTA neutralizing antibody (R&D Systems), granzyme
B activity was mainly detectable in Jurkat T cells. The presence of
isotype control antibody didn’t cause any changes compared to
co-culture in the absence of antibodies. The differences in effects
were also observed in THP-1 cells (Supplementary Figure 5A).
Importantly, granzyme B in T cells is located in acidic granules,
where it doesn’t display catalytic activity since this requiresFrontiers in Immunology | www.frontiersin.org 6neutral (cytosolic) pH (30). By lysing the cells, granzyme B is
co-extracted from the granules, thus enabling the measurement
of its total activity. To confirm that granzyme B displays
increased activity inside living Jurkat T cells in the presence of
THP-1 cells, we measured in-cell activity of the enzyme in resting
PMA (100 nM, 24 h) pre-treated Jurkat T cells after 16 h of
incubation in PMA free medium and in Jurkat T cells (also pre-
treated 24 h with 100 nM PMA) co-cultured for 16 h with PMA-
pre-treated THP-1 cells. Then Jurkat T cells (in suspension) were
separated from THP-1 cells (adherent) and incubated for 1 h at
37°C in the presence of 150 µM Ac-IEPD-AFC (granzyme B
substrate). Cells were then precipitated and fluorescence was
measured against equal amounts of the same cells not exposed to
the substrate. We found that in-cell activity of granzyme B was
significantly increased in Jurkat T cells co-cultured with THP-1
cells (Supplementary Figure 5B).
Our observations suggest that VISTA protein is involved in
galectin-9-induced suppression of granzyme B release from T
cells. Importantly, both VISTA and Tim-3 neutralizing
antibodies used in this study were tested and it was found that
they blocked the effects of the target proteins, but did not induce
any of the downstream effects of their target proteins suggesting
no agonistic properties (data not shown). When recombinant
Tim-3 or VISTA were immobilized on the surface of the ELISA
plate and exposed to galectin-9 for 2 h, galectin-9 was detectable
using ELISA detection antibody. When, before exposure toA B
C
FIGURE 2 | VISTA prevents the release of granzyme B from human T cells into acute myeloid leukemia (AML) cells. THP-1 human AML cells and Jurkat T cells were
pre-treated 24 h with 100 nM phorbol 12-myristate 13-acetate (PMA). Medium was changed and the cells were co-cultured at a ratio of 1:1 for 16 h in the absence
or presence of VISTA-neutralizing antibody or isotype control antibody (A). Levels of secreted galectin-9 were measured by enzyme-linked immunosorbent assays
(ELISA) (B). Granzyme B activity was measured in both THP-1 and Jurkat T cells as outlined in Materials in Methods (C). Data are shown as mean values ± SEM of
four independent experiments; *p < 0.05, **p < 0.01 vs control or indicated events.November 2020 | Volume 11 | Article 580557
Yasinska et al. Galectin-9 and VISTA Ligand-Receptor Interactionsgalectin-9, immobilized proteins were pre-incubated with
corresponding neutralizing antibodies, galectin-9 was no longer
detectable. Neither of the antibodies induced Tim-3 signaling
reported earlier for agonistic anti-Tim-3 antibody (16) or pro-
apoptotic effects in Jurkat T cells expressing VISTA.
We then verified whether human recombinant galectin-9
causes the same effects in PMA-activated Jurkat T cells. We
found that VISTA was present on the surface of Jurkat T cells
regardless of PMA treatment, while Tim-3 mainly appeared on
the cell surface after 24 h of exposure to 100 nM PMA (FigureFrontiers in Immunology | www.frontiersin.org 73A, importantly, expression levels of Tim-3 in Jurkat T cells are
lower compared to AML cells, for example THP-1). The presence
of VISTA was confirmed using immunofluorescent microscopy
(Figure 3B) and the total amounts of both VISTA and Tim-3
were analyzed using FACS (Figure 3C). Exposure of Jurkat T
cells (following 24 h pre-treatment with 100 nM PMA) to 2.5 mg/
ml galectin-9 induced the activation of cell-associated granzyme
B and the effect was downregulated when cells were pre-exposed
(before treatment with galectin-9) to 5 mg/ml Tim-3-neutralizing
or VISTA-neutralizing antibody. The presence of bothA
B
D
E
C
FIGURE 3 | Galectin-9 increases the intracellular activity of granzyme B and upregulates pro-apoptotic processes in Jurkat T cells in a VISTA- and Tim-3-dependent
manner. VISTA and Tim-3 expression on the surface of resting Jurkat T cells and those treated for 24 h with 100 nM PMA was measured using anon-cell Western (A).
VISTA surface expression was confirmed using immunofluorescence microscopy (B). Total cellular levels of Tim-3 and VISTA were measured in permeabilised Jurkat T
cells using flow cytometry (C). Following pre-treatment of Jurkat T cells for 24 h with 100 nM PMA, they were exposed for 24 h to 2.5 µg/ml galectin-9 in the absence or
presence of VISTA or/and Tim-3 neutralizing antibodies. Granzyme B activity was then measured in these cells (D). To assess pro-apoptotic processes Jurkat T cells
were pre-treated for 24 h with 100 nM PMA and then exposed for 24 h to 2.5 µg/ml galectin-9. Caspase-3 activity and PARP cleavage were then measured by
colorimetric assay and Western blot, respectively (E).November 2020 | Volume 11 | Article 580557
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Importantly, this experiment confirmed the role of Jurkat T-
associated VISTA/Tim-3 in galectin-9-induced effects (in this
experiment soluble VISTA/Tim-3 were not present in the
medium but they were present on the surface of Jurkat T cells).
To investigate if galectin-9 induces pro-apoptotic effects in
PMA-activated Jurkat T cells, we exposed them to 2.5 mg/ml
galectin-9 for 16 h and measured caspase-3 activity (colorimetric
assay) as well as poly-ADP-ribose polymerase (PARP) cleavage
(Western blot). We found that caspase-3 activity was
significantly upregulated by galectin-9 and this resulted in a
tendency for increased PARP cleavage (Figure 3E).
To confirm that caspase-3 activation followed by apoptotic
cell death in PMA pre-treated (100 nM, 24 h) Jurkat T cells are
granzyme B-dependent, we exposed these cells to 2.5 mg/ml
galectin-9 for 24 h with or without 30 min pre-treatment with
100 µM Z-AAD-CMK (granzyme B inhibitor). We then assessed
the percentage of apoptotic cells by measuring caspase 3 activity,
using a colorimetric assay, in combination with an annexin V/
propidium iodide assay. In addition, we measured cell viability
using an MTS test. We found that galectin-9-induced caspase-3
activation and apoptotic death were attenuated by the granzyme
B inhibitor (Figure 4).
To further confirm the role of granzyme B in galectin-9-
induced pro-apoptotic processes we used HaCaT cells (non-
malignant human keratinocytes), which express both Tim-3 and
VISTA (Figures 5A–C), but their granzyme B activity was almost
undetectable (Figure 5D). Exposure of HaCaT cells to 2.5 mg/ml
galectin-9 did not result in any further pro-apoptotic effects
(Figures 5D, E). However, caspase-3 activity was slightly
increased after galectin-9 treatment, but the activity level (only
2.67 ± 0.45 pmol/min per mg protein) was still too low to induce
pro-apoptotic processes (approx. 10-fold higher activity is
required for this to occur), which is most likely a result of an
absence of granzyme B activity in HaCaT cells.
To assess differences in the reactivity of T cells and NK cells to
galectin-9 produced by AML cells, we co-cultured 24 h 100 nM
PMA-pre-treated THP-1 AML cells with 24 h 100 nM PMA-pre-
treated Jurkat T cells (co-culture was performed in PMA-free
medium) or primary human NK cells in the absence or presence
of anti-galectin-9 antibody for 16 h. In both cases, secreted
galectin-9 levels were similar when THP-1 and Jurkat T cells
were co-cultured (4.2 ± 0.3 ng/ml) compared to THP-1 cells co-
incubated with primary human NK cells (3.9 ± 0.2 ng/ml). We
found that the presence of THP-1 cells upregulated PARP
cleavage in Jurkat T cells but not in NK cells. This effect was
significantly reduced by the presence of anti-galectin-9 antibody
in Jurkat T cells (as well as caspase-3 activity) and did not have
any influence on the NK cells, which did not produce detectable
amounts of VISTA protein (Figure 6).
Soluble VISTA Induces Apoptotic
Signaling Cascades in T Cells in
Association With Galectin-9
Since recent evidence has clearly demonstrated that VISTA protein
can be secreted by human myeloid cells, we asked whether humanFrontiers in Immunology | www.frontiersin.org 8AML cells produce soluble VISTA. We measured VISTA and
galectin-9 proteins in the blood plasma of 5 newly diagnosed
AML patients and 5 healthy donors. We found that in AML
patients, the levels of both proteins were significantly upregulated
(Figures7A,B). Furthermore, therewas a clear correlationbetween
the levels of both proteins (Figure 7C).
We found that isolated primary human healthy leukocytes
produce around 220 ± 24 pg of galectin-9 per 106 cells and 89 ±
12 pg of soluble VISTA, while primary human AML cells
produced 5980 ± 626 pg of galectin-9 per 106 cells and 707 ±
154 pg of soluble VISTA during 24 h when cultured in vitro
(Supplementary Figure 6A). Using Western blot analysis weFIGURE 4 | Granzyme B is involved in galectin-9-induced caspase-3
activation and apoptotic death of phorbol 12-myristate 13-acetate (PMA)-pre-
treated Jurkat T cells. Jurkat T cells were pre-treated with 100 nM PMA for
24 h followed by 24 h exposure to 2.5 µg/ml galectin-9 with or without
30 min pre-treatment with 100 µM of the granzyme B inhibitor Z-AAD-CMK.
The percentage of apoptotic cells was detected using an annexin V/
propidium iodide assay kit and pro-apoptotic caspase-3 activity was
measured using colorimetric assay. Cell viability was analyzed using an MTS
test. Data are shown as mean values ± SEM of three experiments. *p < 0.05,
**p < 0.01 vs control.November 2020 | Volume 11 | Article 580557
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of AML patients, which was observed at 40 kDa (Supplementary
Figure 6B). This is likely to correspond to the glycosylated
extracellular domain of the protein, because deglycosylation
performed using a deglycosylation kit (Promega) led to a
reduction in molecular weight and the appearance of two new
bands at around 36 and 28 kDa (Supplementary Figure 6B).
Incubation of the samples with deglycosylation enzymes was
performed for 3 h in order to observe the deglycosylation path. A
longer incubation period (18 h) led to the appearance of a 28 kDa
band only (data not shown). Respectively, the bands observedmostFrontiers in Immunology | www.frontiersin.org 9likely correspond to partially and fully deglycosylated protein. The
smallest molecular weight protein is close to that of extracellular
proteindomain (31). SolubleVISTA ismost likely tobeproduced in
a similar manner to soluble Tim-3 and other Ig-type proteins – via
proteolytic shedding. To confirm this we exposed THP-1 cells
(following 24 h pre-treatment with 100 nM PMA) or primary
human AML cells to 100 µM GI254023X (an inhibitor of
angiotensin and metalloproteinase domain-containing proteins
(ADAM) 10/17) or 100 µM batimastat (BB-94, matrix
metalloproteinase inhibitor) for 24 h. Given the similarities
between Tim-3 and VISTA we hypothesized that they may beA
B
D
E
C
FIGURE 5 | Galectin-9 does not induce pro-apoptotic processes in HaCaT keratinocytes which express VISTA but display almost undetectable granzyme B activity.
Expressions of VISTA and Tim-3 were measured on the surface of resting human HaCaT cells (keratinocytes) by on-cell Western (A). VISTA surface expression was
confirmed using immunofluorescence microscopy (B). Total cellular levels of Tim-3 and VISTA were measured in permeabilised HaCaT cells using flow cytometry (C).
HaCaT cells were exposed for 24 h to 2.5 µg/ml galectin-9 followed by measurement of granzyme B activity (D), caspase-3 activity and poly-ADP-ribose polymerase
(PARP) cleavage (E). Images are from one experiment representative of at least four independent experiments which gave similar results. Data are shown as mean
values ± SEM for at least four independent experiments; *p < 0.05 vs control.November 2020 | Volume 11 | Article 580557
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protease inhibitors (5). We found that both inhibitors significantly
reduced the release of soluble VISTA by THP-1 cells, where the
effect of GI254023X was stronger (Figure 7D) and attenuated the
effect in primary AML cells (Figure 7E). These results suggest that,
as with Tim-3, VISTA is mainly shed by ADAM10/17 enzymes.
We then exposed 24 h 100 nM PMA pre-treated Jurkat T cells
to 2.5 µg/ml galectin-9, 5 µg/ml (to assure use of equimolar
amounts of proteins) VISTA or a combination of both proteins
in the indicated concentrations for 16 h. Cells clearly expressed
both receptors (VISTA and Tim-3) as determined by
immunofluorescent microscopy (Figure 8A). We then measured
PARP cleavage as a marker of caspase-3 induced pro-apoptotic
events and found that a combination of galectin-9 and VISTA
significantly increased PARP cleavage and obviously reduced the
total amount of PARP (Figure 8B). In-cell activity of granzyme B
was also significantly increased in the presence of galectin-9 or
VISTA and was further significantly upregulated in the presence of
a combination of both proteins (Figure 8C).
To assess if galectin-9 and VISTA could form complexes
affecting cell polarity (plasma membrane potential), we exposed
24 h 100 nM PMA pre-treated Jurkat T cells to DiBAC4 reactive
dye which concentrates in depolarised cells as outlined in
Materials and Methods and described previously (23). Cells
were treated with 2.5 µg/ml galectin-9 or 5 µg/ml VISTA or a
combination of both proteins at the indicated concentrationsFrontiers in Immunology | www.frontiersin.org 10for 30 min. We then measured fluorescence to characterize cell
membrane potential over a 10 min period. We found that both
galectin-9 and VISTA upregulated fluorescence intensity,
however, the effect was substantially greater when cells were
exposed to a combination of both proteins (Figure 8D). We
hypothesized that soluble VISTA and galectin-9 may form
multiprotein complexes on the T cell surface which may
affect membrane potential and prevent granzyme B release.
We sought to confirm whether the three proteins are capable of
forming a complex and thus performed SRCD spectroscopy of
human recombinant VISTA-Fc (Fc spectra were subtracted),
galectin-9 and Tim-3 as well as an equimolar mixture of all
three proteins (Supplementary Figure 7). There was an
obvious interaction of the three proteins since conformational
changes were seen in the observed spectrum compared to the
simulated spectrum.
We then confirmed the observed effect using primary CD3-
positiveTcells isolated fromthebloodofhealthydonors.These cells
expressed both Tim-3 and VISTA as well as CD3 (a T cell-specific
biological marker) as measured by Western blot analysis (Figure
8E). Cells were exposed for 16 h to 2.5 µg/ml galectin-9 in the
absence or presence of 5 µg/ml VISTA (or 5 µg/ml Fc – the protein
fragment to which the recombinant VISTA is fused). We found
that, as in PMA-activated Jurkat T cells, a combination of both
galectin-9 and VISTA significantly upregulated PARP cleavage,
while the presence of galectin-9 alone non-significantly increased itFIGURE 6 | Galectin-9 produced by acute myeloid leukemia (AML) cells induces pro-apoptotic processes in VISTA-expressing T cells but not in VISTA non-
expressing NK cells. THP-1 human AML cells were pre-treated for 24 h with 100 nM phorbol 12-myristate 13-acetate (PMA). Then they were co-cultured for 16 h
with Jurkat T cells (these cells were also pre-treated with 100 nM PMA for 24 h before co-culturing with THP-1) at a ratio of 1:1or with primary human NK cells at a
ratio of 1 THP-1: 2 NK. Caspase-3 activity and PARP cleavage were then measured in Jurkat T and NK cells as outlined in Materials and Methods. Images are from
one experiment representative of four which gave similar results. Data are shown as mean values ± SEM for four independent experiments; *p < 0.05 vs control.November 2020 | Volume 11 | Article 580557
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FIGURE 7 | Levels of soluble galectin-9 and VISTA are elevated in the blood plasma of acute myeloid
of five healthy donors and five AML patients. Results are shown as mean values ± SEM of five indepen
shown by red lines). (C) Correlation analysis of galectin-9 and VISTA in blood plasma of healthy donors
shedding of VISTA from the surface of phorbol 12-myristate 13-acetate (PMA)-pre-treated (24 h, 100 n
healthy donors or cells which were not exposed to protease inhibitors.
Yasinska et al. Galectin-9 and VISTA Ligand-Receptor Interactions(Figure 8E), which is in linewith the observationsmade in Jurkat T
cells (Figures 8B, C).
Taken together, our results suggest that galectin-9 is a ligand
for VISTA, which can induce granzyme B-dependent
programmed death of T cells, especially in combination with
soluble VISTA. The presence of VISTA in cytotoxic lymphoid
cells may determine their responsiveness to galectin-9.DISCUSSION
Elucidating the reasons for the differential responsiveness of human
NK and T cells to galectin-9 was the main goal of this study. Our
results indicate that human T but not NK cells produce detectable
amounts of the protein VISTA (Figures 1C and 8E), which can act
as immunosuppressive receptor but can also be present in soluble
form and function as a ligand. Immunoprecipitation studies and
biophysical assays (SRCD spectroscopy and SPR) indicated specific
binding of galectin-9 to VISTA with a relatively high affinity (Kd
was 18 nM in surface-free SRCD spectroscopy assay and ~ 100 nM
when analyzed by SPR assay involving protein immobilization on
the surface). Galectin-9 derived fromTHP-1 humanAML cells was
shown to downregulate the release of granzyme B (a pro-apoptoticFrontiers in Immunology | www.frontiersin.org 12proteolytic enzyme) from PMA-activated Jurkat T cells (Figure 2).
As shown inFigure 2, PMA led to both activation of granzyme B in
JurkatT cells and its release intoTHP-1 cells. Exposure of these cells
tobothPMAandcalcium ionophore couldhave led to a higher level
of granzymeBactivation, as indicated inprevious reports (28), but it
would also have led to an artificial increase in cytosolic calcium
levels. Such an effect could normally lead to artificially enhanced
pro-apoptotic effects (32), whereas the aim of our study was to
observe more naturally occurring apoptosis.
Our experiments suggested that pro-apoptotic effects can be
induced by galectin-9 only in cells which express both VISTA and
also produce active granzyme B. This was applicable to PMA-
activated Jurkat T cells (Figures 3 and 4). Furthermore, galectin-9-
induced caspase-3 activation and apoptotic death of these cells were
attenuated by 100 µM Z-AAD-CMK (granzyme B inhibitor),
suggesting the involvement of granzyme B in the process. The
pro-apoptotic effects were not observed in HaCaT keratinocytes
which express both Tim-3 and VISTA but granzyme B activity in
these cells is barely detectable (Figure 5). Primary humanNK cells,
whichexpressTim-3, granzymeBbutnodetectableVISTA,alsodid
not respond pro-apoptotically to galectin-9 released by THP-1
human AML cells (Figure 6). Our results suggest a lack of VISTA
expression in NK cells and are in line with previously reportedA B
D
E
C
FIGURE 8 | Soluble galectin-9 and VISTA induce pro-apoptotic events in VISTA expressing T cells. Jurkat T cells pre-treated for 24 h with 100 nM PMA or primary
human CD3-positive T cells were exposed to human recombinant galectin-9 or/and VISTA. In Jurkat T cells the presence of Tim-3 and VISTA proteins was
confirmed using immunofluorescent microscopy (A). Jurkat T cells were exposed to 2.5 µg/ml galectin-9, 5 µg/ml VISTA or combination of both proteins for 16 h.
Poly-ADP-ribose polymerase (PARP) cleavage was measured using Western blot analysis (B) and in-cell activity of granzyme B – by fluorometric assay (C). Jurkat T
cells were exposed for 30 min to 2.5 µg/ml galectin-9, 5 µg/ml VISTA or a combination of both proteins and plasma membrane potential was measured (D). Primary
human CD3-positive T cells were exposed for 16 h to 2.5 µg/ml galectin-9, 5 µg/ml VISTA (or Fc to confirm specific effect of VISTA) or combination of both proteins,
and PARP cleavage was measured using Western blot analysis. Expression of VISTA, Tim-3, and CD3 was also confirmed using Western blot (E). Images are from
one experiment representative of three which gave similar results. Data are mean values ± SEM of three independent experiments; *p < 0.05 vs control.November 2020 | Volume 11 | Article 580557
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mostly negative for VISTA expression (13–15). All these results
suggest galectin-9-triggeredVITSA/Tim-3-mediated prevention of
granzyme B release from T cells. It is interesting to note that AML
cell-derived galectin-9 induces the same effects as recombinant
protein but in much lower concentrations which suggests that
galectin-9 produced by AML cells displays higher activity
compared to the recombinant one.
AML cells were found to produce high levels of both proteins –
galectin-9 and VISTA (Figure 7). In this study we found that both
PMA-treated THP-1 and primary human AML cells released
soluble forms of galectin-9 and VISTA proteins in high
amounts. Blood plasma of newly diagnosed AML patients
contains significantly greater levels of soluble VISTA and
galectin-9 compared to the blood plasma of healthy donors.
There is a clear correlation between the secretion of these two
proteins (Figures 7A–C). Western blot analysis (before and after
deglycosylation) indicated that blood plasma most likely contains
the glycosylated extracellular domain of VISTA protein (as in the
case of Tim-3, Supplementary Figure 6B). Furthermore, we
found that VISTA (like Tim-3) is shed from the surface of AML
cells by ADAM10/17 proteolytic enzymes (Figures 7D, E).
Interestingly, simultaneous increases in the expressions of
galectin-9, VISTA and Tim-3 were reported for other cancers,
for example gastric cancer (33). Our further experiments indicate
that soluble VISTA significantly enhances the pro-apoptotic effects
of soluble galectin-9 in T cells. This occurs due to changes in cell
polarization/membrane potential (Figure 8D), which may
attenuate the capability of T cells to release granzyme B from
the cell. As a result, granzyme B is released from the acidic
granules in the cell which produced it and thus displays a high
activity within this cell (Figure 8C, Supplementary Figure 5B).
Granzyme B can then induce the classic caspase-3-mediated
apoptotic pathway. Furthermore, galectin-9 could possibly
upregulate granzyme B expression in T cells in a Tim-3-
dependent manner, since presence of the Tim-3-galectin-9
complex on the cell surface leads to activation of NF-kB, which
is known to induce granzyme B expression in these cells (29).
We hypothesized that, given the affinity of Tim-3 and VISTA to
galectin-9, these three proteins may form agglomerates on the cell
surface thereby affecting cell membrane potential/polarization and
the ability to release granzymeB.SRCDexperiments confirmed that
human recombinant VISTA, galectin-9 and Tim-3 can form
agglomerates leading to conformational changes of these proteins.
Importantly, granzyme B displays highest catalytic activity at
neutral pH. Therefore, in cells producing it, this enzyme is stored
in acidic granules to prevent its activation (27, 34). However, when
T cells such as Tregs (regulatoryT cells) andCD8-positive cytotoxic
T cells are ready to release granzyme B (34), formation of the
multiprotein barrier by galectin-9, VISTA and Tim-3 could
potentially lead to its release (leakage) from the granules, thus
resulting in its activationwithin the cells that produce it. Inaddition,
it has been demonstrated that galectin-9 strongly induces calcium
mobilization specifically inT cells (35).Unlike T cells, however, this
effect can be either very mild or absent in myeloid cells (16, 35).
Forming such a barrier around the T cell by galectin-9, VISTA andFrontiers in Immunology | www.frontiersin.org 13Tim-3 will most likely preserve a high calcium concentration in the
T cells, which can then provoke granzyme B release from the
granules and lead to apoptosis induction in granzyme B
expressing cytotoxic T cells and Tregs. In helper T cells, where
granzyme B activity is barely detectable, an increase in intracellular
calcium concentration can lead to calcium-calpain-caspase-
dependent apoptosis (32). In support of this assumption, our
experiments with HaCaT cells showed a slight increase in
caspase-3 activity after exposure to galectin-9 (Figure 5E,
however the actual caspase-3 activity was substantially lower
compared to galectin-9-treated PMA-activated Jurkat T cells),
despite granzyme B activity in these cells is almost undetectable.
Galectin-9-induced apoptotic effects can be stronger in T helper
cells (however, a high concentration of galectin-9 is required (32,
35) than in HaCaT keratinocytes (36), since T cells display strong
pro-apoptotic calcium signaling (32, 35).
Serpin B9 is the endogenous inhibitor of granzyme B, which is
known to be involved in the protection of cytotoxic lymphoid cells
against granzyme B-induced programmed death (37–40). One
could hypothesize that if granzyme B is leaking from the
intracellular granules of T cells, its concentration is higher than
that of serpin B9, similar to the effects observed in NK cells (39).
Jurkat T cells, which we studied, almost lack serpin B9 expression
(40) and thus we observed proapoptotic events in these cells. In
primary T cells, the amount of granzyme B leaking upon exposure
to galectin-9may behigher than those of serpin-9 thus causing pro-
apoptotic events. However, this phenomenon requires further
investigation in order to understand the detailed intracellular
mechanisms leading to galectin-9-induced programmed death of
T lymphocytes. Normally diffusion of granzyme B through
transmembrane pores appears to be the dominant mechanism of
granzyme delivery into the target cells (41, 42). These pores are
formed by the pore-forming protein perforin (41, 42) produced by
NK and cytotoxic T cells. However, upon changes in plasma
membrane potential induced by galectin-9/VISTA, granzyme B
release from T cells is most likely affected. Similar effects were
described in regulatory T cells (Tregs) (43) andNK cells (39) where
granzyme B was shown to leak from cytotoxic granules and induce
self-inflicted damage and programmed cell death.
Our results suggest that intracellular leakage of granzyme B
may be involved in galectin-9-induced VISTA-dependent cell
death too, although other mechanisms, for example calcium-
mediated pro-apoptotic events observed when higher galectin-9
concentrations (1 µM or 32 µg/ml) (32), cannot be ruled out.
Schematically, our hypothesis of the involvement of granzyme B
in VISTA/Tim-3/galectin-9-induced self-killing of T cells is
summarized in Figure 9.
Taken together, our findings demonstrate for the first time that
VISTA interactswith galectin-9with relativelyhigh affinity,without
preventing the interaction of galectin-9with Tim-3. Soluble VISTA
enhances the immunosuppressive activity of galectin-9. Given the
affected plasma membrane potential of the cells exposed to a
combination of galectin-9 and VISTA, one could suggest that
multiprotein complexes are formed by Tim-3, galectin-9 and
VISTA (both T cell surface-based and soluble), thus depolarising
the cell and forming a barrier which prevents the release ofNovember 2020 | Volume 11 | Article 580557
Yasinska et al. Galectin-9 and VISTA Ligand-Receptor Interactionsgranzyme B. On the other hand, it is possible that soluble VISTA
additionally, binds to some other T cells receptors, which remain to
be identified, supporting galectin-9-induced pro-apoptotic effects.
These effects increase granzyme B activity within the cell that
produces it, finally leading to suppressed cellular activity and even
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